Free Trial
NASDAQ:URGN

UroGen Pharma (URGN) Stock Price, News & Analysis

UroGen Pharma logo
$10.40 -0.31 (-2.85%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About UroGen Pharma Stock (NASDAQ:URGN)

Key Stats

Today's Range
$10.34
$10.86
50-Day Range
$9.93
$11.64
52-Week Range
$9.78
$20.70
Volume
494,687 shs
Average Volume
346,041 shs
Market Capitalization
$244.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.20
Consensus Rating
Buy

Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

URGN MarketRank™: 

UroGen Pharma scored higher than 78% of companies evaluated by MarketBeat, and ranked 239th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    UroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    UroGen Pharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about UroGen Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for UroGen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of UroGen Pharma is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of UroGen Pharma is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about UroGen Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    26.27% of the outstanding shares of UroGen Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    UroGen Pharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in UroGen Pharma has recently increased by 2.84%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    UroGen Pharma does not currently pay a dividend.

  • Dividend Growth

    UroGen Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.27% of the outstanding shares of UroGen Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    UroGen Pharma has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in UroGen Pharma has recently increased by 2.84%, indicating that investor sentiment is decreasing.
  • News Sentiment

    UroGen Pharma has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for UroGen Pharma this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,900.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of UroGen Pharma is held by insiders.

  • Percentage Held by Institutions

    91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about UroGen Pharma's insider trading history.
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

UroGen Pharma transferred with Buy rating at Ladenburg
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
UroGen expands cancer portfolio with IconOVir deal
UroGen Pharma's (URGN) Buy Rating Reiterated at D. Boral Capital
UroGen announces results from subgroup analyses of ENVISION trial
See More Headlines

URGN Stock Analysis - Frequently Asked Questions

UroGen Pharma's stock was trading at $10.65 on January 1st, 2025. Since then, URGN shares have decreased by 2.7% and is now trading at $10.36.
View the best growth stocks for 2025 here
.

UroGen Pharma Ltd. (NASDAQ:URGN) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The firm earned $25.20 million during the quarter, compared to analyst estimates of $24.22 million.

UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Top institutional investors of UroGen Pharma include RTW Investments LP (16.35%), Adage Capital Partners GP L.L.C. (12.49%), Toronto Dominion Bank (7.46%) and Toronto Dominion Bank (7.46%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith.
View institutional ownership trends
.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that UroGen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/06/2024
Today
2/21/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.20
High Stock Price Target
$60.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+278.4%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-102,240,000.00
Net Margins
-129.11%
Pretax Margin
-124.59%

Debt

Sales & Book Value

Annual Sales
$82.71 million
Book Value
($2.78) per share

Miscellaneous

Free Float
22,258,000
Market Cap
$242.94 million
Optionable
Optionable
Beta
1.08
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:URGN) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners